Bulletin
Investor Alert

Bio-Techne Corp.

NAS: TECH

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 11, 2021, 4:00 p.m.

/zigman2/quotes/203973516/composite

$

415.54

Change

0.00 0.00%

Volume

Volume 1,429

Quotes are delayed by 20 min

/zigman2/quotes/203973516/composite

Previous close

$ 408.23

$ 415.54

Change

+7.31 +1.79%

Day low

Day high

$394.88

$416.14

Open

52 week low

52 week high

$228.67

$444.83

Open

Company Description

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures...

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Valuation

P/E Current

70.22

P/E Ratio (with extraordinary items)

90.19

P/E Ratio (without extraordinary items)

45.42

Price to Sales Ratio

14.09

Price to Book Ratio

7.35

Price to Cash Flow Ratio

50.70

Enterprise Value to EBITDA

43.76

Enterprise Value to Sales

14.31

Total Debt to Enterprise Value

0.04

Efficiency

Revenue/Employee

321,170.00

Income Per Employee

99,597.00

Receivables Turnover

5.68

Total Asset Turnover

0.36

Liquidity

Current Ratio

4.88

Quick Ratio

3.92

Cash Ratio

2.54

Profitability

Gross Margin

61.81

Operating Margin

21.26

Pretax Margin

37.43

Net Margin

31.01

Return on Assets

11.31

Return on Equity

17.99

Return on Total Capital

9.01

Return on Invested Capital

13.28

Capital Structure

Total Debt to Total Equity

31.39

Total Debt to Total Capital

23.89

Total Debt to Total Assets

20.63

Long-Term Debt to Equity

29.79

Long-Term Debt to Total Capital

22.68

Officers and Executives

Name Age Officer Since Title
Mr. Charles R. Kummeth 58 2013 President, Chief Executive Officer & Director
Mr. James T. Hippel 48 2014 CFO & Principal Accounting Officer
Dr. Robert Monroe - 2018 Chief Medical Officer
Mr. Kim Kelderman - 2018 President-Diagnostics & Genomics
Ms. Brenda Swierenga Furlow 61 2014 Secretary, Senior Vice President & General Counsel

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/01/2021 Kim Kelderman
Pres. Diagnostics & Genom
856   Derivative/Non-derivative trans. at $427.49 per share. 365,931
05/01/2021 Kim Kelderman
Pres. Diagnostics & Genom
1,667   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Charles R. Kummeth
Chief Executive Officer; Director
17,428   Derivative/Non-derivative trans. at $411 per share. 7,162,908
02/16/2021 Charles R. Kummeth
Chief Executive Officer; Director
30,000   Derivative/Non-derivative trans. at $94.35 per share. 2,830,500
02/12/2021 James T. Hippel
Chief Financial Officer
600   Disposition at $401.52 per share. 240,912
02/12/2021 James T. Hippel
Chief Financial Officer
9,400   Disposition at $400.32 per share. 3,763,008
02/12/2021 Brenda Swierenga Furlow
SVP - General Counsel
3,326   Disposition at $399.12 per share. 1,327,473
02/12/2021 Brenda Swierenga Furlow
SVP - General Counsel
6,674   Disposition at $398.4 per share. 2,658,921
02/12/2021 James T. Hippel
Chief Financial Officer
10,000   Derivative/Non-derivative trans. at $106.59 per share. 1,065,900
02/12/2021 Brenda Swierenga Furlow
SVP - General Counsel
10,000   Derivative/Non-derivative trans. at $106.59 per share. 1,065,900
02/08/2021 Roeland Nusse
Director
6,000   Disposition at $385.08 per share. 2,310,480
02/08/2021 Roeland Nusse
Director
5,000   Derivative/Non-derivative trans. at $66.9 per share. 334,500
02/08/2021 Roeland Nusse
Director
1,000   Derivative/Non-derivative trans. at $70.35 per share. 70,350
02/05/2021 Kim Kelderman
Pres. Diagnostics & Genom
823   Disposition at $388.45 per share. 319,694
02/05/2021 Norman David Eansor
President-Protein Sciences
1,100   Disposition at $385.59 per share. 424,149
02/05/2021 Norman David Eansor
President-Protein Sciences
1,900   Disposition at $384.15 per share. 729,885
02/05/2021 Norman David Eansor
President-Protein Sciences
3,700   Disposition at $382.6 per share. 1,415,620
02/05/2021 Norman David Eansor
President-Protein Sciences
2,900   Disposition at $381.52 per share. 1,106,408
02/05/2021 Norman David Eansor
President-Protein Sciences
12,833   Disposition at $380.5 per share. 4,882,956
02/05/2021 Norman David Eansor
President-Protein Sciences
4,500   Disposition at $379.62 per share. 1,708,290
02/05/2021 Norman David Eansor
President-Protein Sciences
6,000   Disposition at $378.29 per share. 2,269,740
02/05/2021 Norman David Eansor
President-Protein Sciences
18,819   Derivative/Non-derivative trans. at $106.59 per share. 2,005,917
02/05/2021 Norman David Eansor
President-Protein Sciences
14,114   Derivative/Non-derivative trans. at $106.59 per share. 1,504,411
01/15/2021 Charles R. Kummeth
Chief Executive Officer; Director
20,000   Disposition at $344 per share. 6,880,000
01/11/2021 James T. Hippel
Chief Financial Officer
2,009   Disposition at $334.98 per share. 672,974
01/11/2021 James T. Hippel
Chief Financial Officer
3,990   Disposition at $334.39 per share. 1,334,216
01/11/2021 James T. Hippel
Chief Financial Officer
2,501   Disposition at $333.23 per share. 833,408
01/11/2021 James T. Hippel
Chief Financial Officer
700   Disposition at $331.61 per share. 232,127
01/11/2021 James T. Hippel
Chief Financial Officer
400   Disposition at $330.26 per share. 132,104
01/11/2021 James T. Hippel
Chief Financial Officer
400   Disposition at $328.68 per share. 131,472
01/11/2021 James T. Hippel
Chief Financial Officer
10,000   Derivative/Non-derivative trans. at $106.59 per share. 1,065,900
12/07/2020 Charles R. Kummeth
Chief Executive Officer; Director
5,000   Disposition at $308 per share. 1,540,000
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel
707   Disposition at $302.82 per share. 214,093
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel
6,783   Disposition at $302.15 per share. 2,049,483
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel
3,367   Disposition at $301.32 per share. 1,014,544
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel
938   Derivative/Non-derivative trans. at $106.59 per share. 99,981
11/30/2020 Brenda Swierenga Furlow
SVP - General Counsel
10,857   Derivative/Non-derivative trans. at $106.59 per share. 1,157,247
11/18/2020 Robert V. Baumgartner
Director
5,000   Disposition at $303.34 per share. 1,516,700
11/18/2020 Robert V. Baumgartner
Director
5,000   Derivative/Non-derivative trans. at $66.9 per share. 334,500
/news/latest/company/us/tech

MarketWatch News on TECH

  1. Bio-Techne stock price target raised to $460 from $410 at Benchmark

    6:21 a.m. April 13, 2021

    - Tomi Kilgore

  2. Bio-Techne upgraded to buy from hold at Stifel Nicolaus

    8:35 a.m. Feb. 23, 2021

    - Tomi Kilgore

  3. Bio-Techne stock price target raised to $400 from $310 at Stifel Nicolaus

    8:27 a.m. Feb. 3, 2021

    - Tomi Kilgore

  4. Bio-Techne started at sector weight with $340 stock fair value estimate at KeyBanc Capital

    7:28 a.m. Nov. 10, 2020

    - Tomi Kilgore

  5. Bio-Techne downgraded to hold from buy at Stifel Nicolaus

    6:49 a.m. May 27, 2020

    - Tomi Kilgore

  6. Bio-Techne started at buy with $290 stock price target at Benchmark

    6:25 a.m. May 14, 2020

    - Tomi Kilgore

  7. The Investment Allure of American Water Works

    10:30 p.m. Jan. 10, 2020

    - Barron's Online

  8. How to profit from the ‘best of both worlds’ in stock investing

    10:20 a.m. Sept. 23, 2019

    - Philip van Doorn

  9. The Best Mutual Funds You’ve Never Heard Of

    5:28 p.m. July 12, 2019

    - Barron's Online

  10. Five Ways to Play a Growing Health Sector

    1:40 a.m. Jan. 19, 2019

    - Barron's Online

  11. Bio-Techne stock value estimate raised to $180 from $148 at Janney

    2:01 p.m. Aug. 9, 2018

    - Tomi Kilgore

  12. These two trends will continue to power small-cap stocks

    7:50 a.m. July 19, 2018

    - Philip van Doorn

  13. 3 Growth Stocks for the Long Haul

    1:08 p.m. March 7, 2018

    - Barron's Online

  14. What Happened In Pharma Last Quarter?

    9:19 a.m. Aug. 18, 2017

    - Barrons Blogs

  15. Bio-Techne downgraded to neutral from buy at Janney

    7:56 a.m. March 27, 2017

    - Tomi Kilgore

  16. Bio-Techne started at buy with $115 stock price target at Deutsche Bank

    9:45 a.m. Jan. 18, 2017

    - Tomi Kilgore

  17. Loading more headlines...
/news/nonmarketwatch/company/us/tech

Other News on TECH

  1. 10-Q: BIO-TECHNE CORP

    4:35 p.m. May 7, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  2. Bio-Techne Corp (TECH) Q3 2021 Earnings Call Transcript

    1:31 a.m. May 7, 2021

    - Motley Fool

  3. Bio-Techne Q3 2021 Earnings Preview

    1:07 p.m. May 5, 2021

    - Seeking Alpha

  4. Notable earnings before Thursday's open

    12:48 p.m. May 5, 2021

    - Seeking Alpha

  5. 8 Great Index Funds for Indecisive Investors

    1:41 p.m. April 22, 2021

    - InvestorPlace.com

  6. Bio-Techne seals Asuragen acquisition

    4:14 p.m. April 6, 2021

    - Seeking Alpha

  7. Stifel upgrades Bio-Techne to buy from hold, boosts price target

    11:57 a.m. Feb. 23, 2021

    - Seeking Alpha

  8. Bio-Techne signs a license agreement with Luminary Therapeutics

    8:19 a.m. Feb. 23, 2021

    - Seeking Alpha

  9. Tracking Ron Baron's BAMCO Portfolio - Q4 2020 Update

    11:32 p.m. Feb. 21, 2021

    - Seeking Alpha

  10. 10-Q: BIO-TECHNE CORP

    7:33 a.m. Feb. 8, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  11. Bio-Techne FQ2 2021 Earnings Preview

    1:32 p.m. Feb. 1, 2021

    - Seeking Alpha

  12. Tracking Ron Baron's BAMCO Portfolio - Q3 2020 Update

    6:20 a.m. Dec. 22, 2020

    - Seeking Alpha

  13. Loading more headlines...

At a Glance

Bio-Techne Corp.

614 McKinley Place NE

Minneapolis, Minnesota 55413-2610

Phone

1 6123792956

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

06/2021

Revenue

$738.69M

Net Income

$229.07M

2020 Sales Growth

3.5%

Employees

2,300

/news/pressrelease/company/us/tech

Press Releases on TECH

  1. Bio-Techne Corp. to Host Earnings Call

    7:16 a.m. May 6, 2021

    - ACCESSWIRE

  2. Bio-Techne Releases Third Quarter Fiscal 2021 Results

    6:30 a.m. May 6, 2021

    - PR Newswire - PRF

  3. Bio-Techne Declares Dividend

    6:30 a.m. May 6, 2021

    - PR Newswire - PRF

  4. 908 Devices and Bio-Techne Announce Joint Collaboration

    12:21 p.m. May 4, 2021

    - BusinessWire - BZX

  5. Bio-Techne and 908 Devices Announce Joint Collaboration

    7:00 a.m. May 4, 2021

    - PR Newswire - PRF

  6. Loading more headlines...
Link to MarketWatch's Slice.